SUNDAY, JUNE 25, 2017

MenB vaccine added to England’s national childhood immunization program

Beginning Sept. 1,  the MenB vaccine will be part of England's National Health Service's Childhood Immunization Program. Read More »

Study shows immune cells -- not HIV particles -- cause AIDS

Scientists from the Gladstone Institutes recently conducted a study that shows HIV is not responsible for AIDS, rather it’s the host’s immune cells responding to the virus because of how the cells lethally influence each other. Read More »

Valneva unveils two recent EB66 agreements

Valneva recently announced that it has signed two new EB66 agreements with Kaketsuken, which is a Japanese pharmaceutical company, and Fatro, an Italian firm. Read More »

Novavax names vice president of finance

Novavax, Inc., a clinical-stage vaccine company that specializes in the development, discovery and commercialization of recombinant nanoparticle vaccines and adjuvants, named Chris Dunne as its new vice president of finance Read More »

Doctors overestimate their Ebola assessment abilities

A recent survey of primary care physicians show that many of them overestimate their own abilities to assess potential Ebola cases and explain the risks of Ebola to their patients. Read More »

Immunomic Therapeutics to present at Swiss Skin Vaccination Summit

Immunomic Therapeutics Inc., a privately held biotechnology company that creates vaccines using its proprietary LAMP technology, recently announced that a company representative will give a presentation at the Skin Vaccination Summit taking place in Lausanne, Switzerland, from Sept. 2 to 4. Read More »

MRF welcomes new MenB vaccine introduction

The MRF recently welcomed the world’s first comprehensive vaccination program specifically dedicated to protecting babies from meningococcal B (MenB) meningitis as well as septicaemia with the immunization program in the U.K. Read More »

World Molecular Imaging Congress focuses on HuMab 5B1 antibody

MabVax Therapeutics Holdings Inc., a clinical stage oncology drug development company, recently announced that its top antibody, HuMab 5B1, will be the main focus at the World Molecular Imaging Congress (WMIC). Read More »

Newly discovered hepatovirus could help develop hepatitis A treatments

The discovery of a new hepatovirus, phopivirus of seals, which is related to the human hepatitis A virus, may help researchers develop new treatments for hepatitis A. Read More »